Replies to post #84944 on Biotech Values

[DewDiligence]

MNTA should just offer to pay the FDA the standard NDA fee - grease the wheels a bit! Seems a tad unfair that FoBs can end up in regulatory limbo for a near indefinite period of time.

Generic Lovenox is not an FoB. Perhaps you meant to say that the Lovenox application is an ANDA, which does not have a formal review timeline.

If there were a way to expedite an ANDA review by paying a fee, I’m sure NVS (the official applicant in this case) would have done that.